Telomir Pharmaceuticals’ new drug reverses insulin resistance in diabetes study (opens in new tab)

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy on 15 June 2026, reporting that its investigational small molecule Telomir-Zn restored insulin sensitivity in a diet-induced zebrafish model of type 2 diabetes. According to the company, treated zebrafish showed dose-dependent improvements across multiple measures: fasting blood glucose declined to near control […] The post appeared first on <a href="